Vir Biotechnology, Inc. announced that Mark D. Eisner, M.D., M.P.H. will join the company as Executive Vice President and Chief Medical Officer , effective June 03, 2024. Dr. Eisner will be a part of.
The FDA granted priority review to inavolisib plus palbociclib/fulvestrant for HR-positive, HER2-negative, advanced breast cancer with PIK3CA mutations.
Merck Sees Pipeline Diversification Opportunity in $1 3B EyeBio Acquisition medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.
Merck to Acquire EyeBio for Up to $3B, Re-Entering Eye Drug Space genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
Tremendous progress has been made in the treatment landscape for HER2-positive breast cancer that has significantly altered and improved the outlook for this patient population.